2022 Taiwan lipid guidelines for primary prevention

Po-Hsun Huang; Ya-Wen Lu; Yi-Lin Tsai; Yen-Wen Wu; Hung-Yuan Li; Hsin-Yun Chang; Chih-Hsing Wu; Chih-Yu Yang; Der-Cherng Tarng; Chin-Chou Huang; Li-Ting Ho; Chao-Feng Lin; Shih-Chieh Chien; Yih-Jer Wu; Hung-I Yeh; Wen-Harn Pan; Yi-Heng Li; expert committee for the Taiwan Lipid Guidelines for Primary Prevention

doi:10.1016/j.jfma.2022.05.010

2022 Taiwan lipid guidelines for primary prevention

J Formos Med Assoc. 2022 Dec;121(12):2393-2407. doi: 10.1016/j.jfma.2022.05.010. Epub 2022 Jun 14.

Authors

Po-Hsun Huang¹, Ya-Wen Lu¹, Yi-Lin Tsai¹, Yen-Wen Wu², Hung-Yuan Li³, Hsin-Yun Chang⁴, Chih-Hsing Wu⁵, Chih-Yu Yang⁶, Der-Cherng Tarng⁷, Chin-Chou Huang⁸, Li-Ting Ho⁹, Chao-Feng Lin¹⁰, Shih-Chieh Chien¹¹, Yih-Jer Wu¹⁰, Hung-I Yeh¹⁰, Wen-Harn Pan¹², Yi-Heng Li¹³; expert committee for the Taiwan Lipid Guidelines for Primary Prevention

Affiliations

¹ Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Clinical Medicine and Cardiovascular Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan.
² Division of Cardiology, Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan; Department of Nuclear Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
³ Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
⁴ Department of Family Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Institute of Allied Health Science, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
⁵ Department of Family Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Institute of Gerontology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
⁶ Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Clinical Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
⁷ Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Department and Institute of Physiology, National Yang Ming Chiao Tung University, Taipei, Taiwan.
⁸ Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
⁹ Division of Cardiology, Department of Internal Medicine, National Taiwan University College of Medicine and Hospital, Taiwan; Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taiwan.
¹⁰ Cardiovascular Center, Department of Medical Research, MacKay Memorial Hospital, New Taipei City, Taiwan; Department of Medicine, MacKay Medical College, New Taipei City, Taiwan.
¹¹ Department of Medicine, MacKay Medical College, New Taipei City, Taiwan; Department of Critical Care Medicine, MacKay Memorial Hospital, Taipei, Taiwan; Division of Cardiology, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan.
¹² Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
¹³ Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Electronic address: heng@mail.ncku.edu.tw.

PMID: 35715290
DOI: 10.1016/j.jfma.2022.05.010

Abstract

Elevated circulating low-density lipoprotein cholesterol (LDL-C) is a major risk factor of atherosclerotic cardiovascular disease (ASCVD). Early control of LDL-C to prevent ASCVD later in life is important. The Taiwan Society of Lipids and Atherosclerosis in association with the other seven societies developed this new lipid guideline focusing on subjects without clinically significant ASCVD. In this guideline for primary prevention, the recommended LDL-C target is based on risk stratification. A healthy lifestyle with recommendations for foods, dietary supplements and alcohol drinking are described. The pharmacological therapies for LDL-C reduction are recommended. The aim of this guideline is to decrease the risk of ASCVD through adequate control of dyslipidemia in Taiwan.

Keywords: Atherosclerosis; Cholesterol; Taiwan.

Publication types

Practice Guideline

MeSH terms

Atherosclerosis* / prevention & control
Cardiovascular Diseases* / complications
Cardiovascular Diseases* / prevention & control
Cholesterol, LDL
Dyslipidemias*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
Primary Prevention
Risk Factors
Taiwan

Substances

Cholesterol, LDL
Hydroxymethylglutaryl-CoA Reductase Inhibitors